| |
| Issue |
Title |
| |
| Vol 63, No 2 (2025) |
Cytological taxonomy of chronic pain in rheumatoid arthritis: A brief descriptive review |
Abstract
PDF (Rus)
|
|
A. Е. Karateev, E. Yu. Polishchuk |
| |
| Vol 63, No 1 (2025) |
Radiomics as a new frontier in modern rheumatology: Chest pathology visualization advances and prospects |
Abstract
PDF (Rus)
|
|
T. V. Beketova, E. L. Nasonov, M. A. Alekseev, E. I. Shchepikhin, Yu. N. Philippovich, A. S. Kruzhalov, A. Yu. Philippovich, V. A. Kulbak, D. A. Argunova, P. G. Shakhnovich, T. A. Prazdnichnykh, M. P. Obidin, T. N. Krasnova, N. N. Vladimirova |
| |
| Vol 62, No 6 (2024) |
The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, T. V. Beketova, A. M. Satybaldyev |
| |
| Vol 62, No 4 (2024) |
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6 |
Abstract
PDF (Rus)
|
|
Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov |
| |
| Vol 62, No 3 (2024) |
Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. G. Rumyantsev, M. Yu. Samsonov |
| |
| Vol 62, No 2 (2024) |
Interleukin 17 as a central component of the pathogenesis of pain associated with immunoinflammatory process: A new “target” of pharmacotherapy |
Abstract
PDF (Rus)
|
|
А. Е. Karateev, Е. Yu. Polishchuk, Т. V. Dubinina |
| |
| Vol 62, No 1 (2024) |
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 61, No 6 (2023) |
Blockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolism |
Abstract
PDF (Rus)
|
|
L. V. Kondratyeva, Yu. S. Gorbunova, T. V. Popkova, E. L. Nasonov |
| |
| Vol 61, No 4 (2023) |
Monogenic autoinflammatory syndromes with features of systemic vasculitis: a new field of rheumatology |
Abstract
PDF (Rus)
|
|
T. V. Beketova, M. F. Beketova, E. L. Nasonov |
| |
| Vol 61, No 3 (2023) |
Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva, D. A. Dibrov |
| |
| Vol 61, No 2 (2023) |
The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors? |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva, T. V. Korotaeva, T. V. Dubinina, Ju. V. Usacheva |
| |
| Vol 61, No 1 (2023) |
Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra) |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, Z. N. Sukmarova, T. V. Popkova, B. S. Belov |
| |
| Vol 60, No 6 (2022) |
Axial involvement in psoriatic arthritis |
Abstract
PDF (Rus)
|
|
E. E. Gubar, T. V. Korotaeva |
| |
| Vol 60, No 5 (2022) |
Pathophysiology of iron and hepcidin metabolism: research perspectives in rheumatolog |
Abstract
PDF (Rus)
|
|
A. M. Lila, E. A. Galushko, A. S. Semashko |
| |
| Vol 60, No 3 (2022) |
The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist) |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, M. Yu. Samsonov |
| |
| Vol 60, No 2 (2022) |
Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva |
| |
| Vol 60, No 1 (2022) |
Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data |
Abstract
PDF (Rus)
PDF (Eng)
|
|
E. L. Nasonov, T. V. Korotaeva, S. Rodolfi, C. F. Selmi |
| |
| Vol 59, No 2 (2021) |
Use of tanezumab for chronic pain treatment |
Abstract
PDF (Rus)
|
|
A. E. Karateev, A. M. Lila, L. I. Alekseeva |
| |
| Vol 58, No 6 (2020) |
Direct-acting oral anticoagulants in antiphospholipid syndrome |
Abstract
PDF (Rus)
|
|
T. M. Reshetnyak, K. S. Nurbaeva |
| |
| Vol 58, No 5 (2020) |
Current therapy of interstitial pneumonia associated with systemic scleroderma |
Abstract
PDF (Rus)
|
|
L. P. Ananieva |
| |
| Vol 58, No 5 (2020) |
The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases |
Abstract
PDF (Rus)
PDF (Eng)
|
|
E. L. Nasonov, A. M. Lila |
| |
| Vol 58, No 4 (2020) |
Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib |
Abstract
PDF (Rus)
|
|
A. E. Karateev |
| |
| Vol 58, No 3 (2020) |
BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. M. Lila |
| |
| Vol 58, No 2 (2020) |
EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II) |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva, A. M. Lila |
| |
| Vol 58, No 1 (2020) |
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I) |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva, A. M. Lila |
| |
| Vol 57, No 6 (2019) |
Cell technologies in the treatment of rheumatic diseases |
Abstract
PDF (Rus)
|
|
N. F. Soroka, M. P. Potapnev, N. A. Martusevich |
| |
| Vol 57, No 5 (2019) |
The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. M. Lila |
| |
| Vol 57, No 4 (2019) |
IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, A. S. Avdeeva |
| |
| Vol 57, No 3 (2019) |
Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders |
Abstract
PDF (Rus)
|
|
T. A. Lisitsyna, D. Yu. Veltishchev, A. M. Lila, E. L. Nasonov |
| |
| Vol 57, No 2 (2019) |
Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs |
Abstract
PDF (Rus)
|
|
A. E. Karateev, E. L. Nasonov |
| |
| Vol 57, No 1 (2019) |
Psychological stress and rheumatoid arthritis – interference of pathogenetic mechanisms |
Abstract
PDF (Rus)
|
|
N. O. Tuaeva, A. E. Nosyrev, Y. Renaudineau, M. I. Arleevskaya |
| |
| Vol 56, No 6 (2018) |
Angiotensins and rheumatoid arthritis |
Abstract
PDF (Rus)
|
|
N. M. Savushkina, E. A. Galushko, N. V. Demidova, A. V. Gordeev |
| |
| Vol 56, No 5 (2018) |
IS PERIODONTITIS A HARBINGER OF RHEUMATOID ARTHRITIS? |
Abstract
PDF (Rus)
|
|
A. V. Gordeev, E. A. Galushko, N. M. Savushkina, A. M. Lila |
| |
| Vol 56, No 4 (2018) |
MACROPHAGE FUNCTIONAL DISORDERS IN RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS |
Abstract
PDF (Rus)
|
|
E. V. Gerasimova, T. V. Popkova |
| |
| Vol 56, No 2 (2018) |
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY |
Abstract
PDF (Rus)
|
|
T. V. Beketova, M. A. Ushakova, N. Yu. Nikishina, A. N. Khelkovskaya-Sergeeva, E. V. Nikolaeva, E. G. Sazhina, T. M. Novoselova, E. L. Nasonov |
| |
| Vol 56, No 1 (2018) |
OSTEOARTHRITIS: CURRENT CLINICAL CONCEPT AND SOME PROMISING THERAPEUTIC APPROACHES |
Abstract
PDF (Rus)
|
|
A. E. Karateev, A. M. Lila |
| |
| Vol 55, No 5 (2017) |
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE |
Abstract
PDF (Rus)
|
|
T. V. Beketova, E. L. Nasonov |
| |
| Vol 55, No 4 (2017) |
PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 55, No 3 (2017) |
PROBLEMS OF RHEUMATOID ARTHRITIS IMMUNOPATHOLOGY: EVOLUTION OF THE DISEASE |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 55, No 2 (2017) |
DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, V. I. Mazurov, Yu. V. Usacheva, E. V. Chernyaeva, Ya. Yu. Ustyugov, A. B. Ulitin, R. A. Ivanov |
| |
| Vol 55, No 1 (2017) |
PAIN AND INFLAMMATION. PART 2. THE ANALGESIC POTENTIAL OF ANTI-INFLAMMATORY DRUGS |
Abstract
PDF (Rus)
PDF (Eng)
|
|
A. E. Karateev, D. E. Karateev, O. S. Davydov |
| |
| Vol 55, No 1 (2017) |
NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17 |
Abstract
PDF (Rus)
PDF (Eng)
|
|
E. L. Nasonov |
| |
| Vol 54, No 6 (2016) |
PAIN AND INFLAMMATION. PART 1. PATHOGENETIC ASPECTS |
Abstract
PDF (Rus)
PDF (Eng)
|
|
A. E. Karateev, D. E. Karateev, O. S. Davydov |
| |
| Vol 54, No 5 (2016) |
THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
Abstract
PDF (Rus)
PDF (Eng)
|
|
Yu. L. Korsakova, L. N. Denisov |
| |
| Vol 54 (2016): приложение 2 |
METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 54, No 4 (2016) |
The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis |
Abstract
PDF (Rus)
|
|
A. S. Avdeeva, Yu. P. Rubtsov, D. T. Dyikanov, E. L. Nasonov |
| |
| Vol 54 (2016): приложение 1 |
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS |
Abstract
PDF (Rus)
|
|
Sh. F. Erdes |
| |
| Vol 54, No 3 (2016) |
CURRENT APPROACHES TO THE LABORATORY DIAGNOSIS OF RHEUMATIC DISEASES: ROLE OF MOLECULAR AND CELLULAR BIOMARKERS |
Abstract
PDF (Rus)
|
|
E. N. Aleksandrova, A. A. Novikov, E. L. Nasonov |
| |
| Vol 54, No 2 (2016) |
THE CONCEPT OF BARRIER ORGAN DISEASE IN THE PATHOGENESIS OF SPONDYLOARTHRITIS |
Abstract
PDF (Rus)
|
|
E. A. Galushko, A. V. Gordeev |
| |
| Vol 54, No 1 (2016) |
ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, M. S. Eliseev |
| |
| Vol 53, No 6 (2015) |
PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS |
Abstract
PDF (Rus)
|
|
L. P. Ananyeva |
| |
| Vol 53, No 5 (2015) |
ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 53, No 4 (2015) |
METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| Vol 53, No 3 (2015) |
MODERN IDEA ON THE PATHOGENESIS OF SPONDYLOARTHRITIS: MOLECULAR MECHANISMS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, E. A. Galushko, A. V. Gordeev |
| |
| Vol 53, No 2 (2015) |
MAST CELLS ARE KEY PARTICIPANTS IN THE PATHOGENESIS OF IMMUNOINFLAMMATORY DISEASES |
Abstract
PDF (Rus)
|
|
E. O. Baglay, A. I. Dubikov |
| |
| Vol 53, No 1 (2015) |
IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE |
Abstract
PDF (Rus)
|
|
E. V. Suponitskaya, E. N. Aleksandrova, A. P. Aleksankin, E. L. Nasonov |
| |
| Vol 52, No 6 (2014) |
VACCINATION IN RHEUMATOLOGY: CURRENT ASPECTS |
Abstract
PDF (Rus)
|
|
B. S. Belov, M. S. Naumtseva, G. M. Tarasova, M. V. Polyanskaya |
| |
| Vol 52, No 5 (2014) |
CLINICAL SIGNIFICANCE OF BAFF/BLyS AND APRIL IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS |
Abstract
PDF (Rus)
|
|
E. V. Suponitskya, E. N. Aleksandrova, E. L. Nasonov |
| |
| Vol 52, No 4 (2014) |
T-REGULATORY CELLS IN RHEUMATOID ARTHRITIS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, E. N. Aleksandrova, A. S. Avdeeva, Yu. P. Rubtsov |
| |
| Vol 52, No 3 (2014) |
PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS |
Abstract
PDF (Rus)
|
|
E. L. Nasonov, S. K. Solovyev |
| |
| Vol 52, No 2 (2014) |
NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB |
Abstract
PDF (Rus)
|
|
E. L. Nasonov |
| |
| 1 - 61 of 61 Items |
|
